WHY IT MATTERS: Patients seeking medical cannabis products manufactured to pharmaceutical standards may find broader availability and greater product consistency if U.S. federal policy changes open legitimate pathways for GMP-certified producers to scale and export. CLINICAL OVERVIEW: Federal policy shifts around cannabis scheduling and executive action have historically created both opportunity and uncertainty for companies operating at the intersection of pharmaceutical-grade cannabis and international markets. When regulatory frameworks begin to clarify, manufacturers with established GMP infrastructure and clinical trial experience are better positioned to meet the evidentiary standards that pharmaceutical buyers and foreign health authorities require.
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.
Urgent need for clinical trials investigating the effects of cannabinoids on hormone receptor-positive breast cancer therapy
Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment In Summary Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70-80% of BC cases fall into the category of hormone...